title: Technique and results of hyperthermic (41 degrees C) isolated lung perfusion with high-doses of cisplatin for the treatment of surgically relapsing or unresectable lung sarcoma metastasis.
abstract: OBJECTIVE
  A technique of hyperthermic isolated lung perfusion (ILP) chemotherapy was developed.
  
  
  METHODS
  Since April 1999, four patients with unilateral (n=2) or bilateral (n=2) sarcoma metastasis confined to a lobe (n=2) or entire lung (n=2) entered into a pilot study of hyperthermic (41 degrees C) ILP with high doses of cisplatin (70 mg/m(2)). Eligibility included drug resistant metastasis and at least four previous surgical metastectomies. The ILP of the lung segments was carried out following metastectomy, for 20-40 min at a rate of 0.3-0.5 l/min, a mean perfusion pressure lower than the own mean pulmonary artery pressure, and an inflow temperature of 41 degrees C or higher. Before and following ILP, the isolated lung segments were flushed with normothermic saline (1 l). Flow was continuously maintained by a centrifugal pump.
  
  
  RESULTS
  All patients successfully completed 31.7+/-9 min perfusion time at 41.4+/-0.3 degrees C, and this time-point corresponded to the maximal platinum lung-uptake (93.8 ng/mg tissue). The total vascular isolation was confirmed by continuously low systemic cisplatin plasma levels. There was no systemic drug-related toxicity but all patients experienced transient pulmonary toxicity as non-cardiogenic edema of the treated lung segments. With a median follow-up of 12 months, three patients are alive and disease-free and one died from cerebral metastasis without autopsy evidence of local recurrence 13 months following ILP.
  
  
  CONCLUSIONS
  Hyperthermic perfusion chemotherapy can be done safely and effectively. It represents a new treatment modality and deserves further investigations for patients with advanced, drug resistant or surgically refractory, lung sarcoma metastasis. However, further studies are needed to limit the ILP-induced pulmonary toxicity.
authors.affiliation: Division of Cardio-thoracic and Vascular Surgery, Hannover Medical School, Hannover, Germany.
authors.forename: Carsten
authors.initials: C
authors.lastname: Schröder
authors.forename: Stefan
authors.initials: S
authors.lastname: Fisher
authors.forename: Anne Christin
authors.initials: AC
authors.lastname: Pieck
authors.forename: Axel
authors.initials: A
authors.lastname: Müller
authors.forename: Ulrich
authors.initials: U
authors.lastname: Jaehde
authors.forename: Hartmut
authors.initials: H
authors.lastname: Kirchner
authors.forename: Axel
authors.initials: A
authors.lastname: Haverich
authors.forename: Paolo
authors.initials: P
authors.lastname: Macchiarini
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage*; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000628:therapy*; D008297:Male; D012509:Sarcoma / Q000188:drug therapy / Q000556:secondary / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin